280 related articles for article (PubMed ID: 34066732)
1. Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies.
Lodewijckx I; Cools J
Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34066732
[TBL] [Abstract][Full Text] [Related]
2. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
3. MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia.
Canté-Barrett K; Spijkers-Hagelstein JA; Buijs-Gladdines JG; Uitdehaag JC; Smits WK; van der Zwet J; Buijsman RC; Zaman GJ; Pieters R; Meijerink JP
Leukemia; 2016 Sep; 30(9):1832-43. PubMed ID: 27174491
[TBL] [Abstract][Full Text] [Related]
4. IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update.
Oliveira ML; Akkapeddi P; Ribeiro D; Melão A; Barata JT
Adv Biol Regul; 2019 Jan; 71():88-96. PubMed ID: 30249539
[TBL] [Abstract][Full Text] [Related]
5. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
6. Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Degryse S; de Bock CE; Demeyer S; Govaerts I; Bornschein S; Verbeke D; Jacobs K; Binos S; Skerrett-Byrne DA; Murray HC; Verrills NM; Van Vlierberghe P; Cools J; Dun MD
Leukemia; 2018 Mar; 32(3):788-800. PubMed ID: 28852199
[TBL] [Abstract][Full Text] [Related]
7. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain.
Kirken RA; Rui H; Malabarba MG; Howard OM; Kawamura M; O'Shea JJ; Farrar WL
Cytokine; 1995 Oct; 7(7):689-700. PubMed ID: 8580378
[TBL] [Abstract][Full Text] [Related]
8. TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.
Pike KA; Tremblay ML
Cytokine; 2016 Jun; 82():52-7. PubMed ID: 26817397
[TBL] [Abstract][Full Text] [Related]
9. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.
Kirken RA; Erwin RA; Wang L; Wang Y; Rui H; Farrar WL
J Immunol; 2000 Nov; 165(9):5097-104. PubMed ID: 11046040
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
[TBL] [Abstract][Full Text] [Related]
11. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.
Barata JT; Silva A; Brandao JG; Nadler LM; Cardoso AA; Boussiotis VA
J Exp Med; 2004 Sep; 200(5):659-69. PubMed ID: 15353558
[TBL] [Abstract][Full Text] [Related]
12. The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3.
Habib T; Senadheera S; Weinberg K; Kaushansky K
Biochemistry; 2002 Jul; 41(27):8725-31. PubMed ID: 12093291
[TBL] [Abstract][Full Text] [Related]
13. JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL.
Wahnschaffe L; Braun T; Timonen S; Giri AK; Schrader A; Wagle P; Almusa H; Johansson P; Bellanger D; López C; Haferlach C; Stern MH; Dürig J; Siebert R; Mustjoki S; Aittokallio T; Herling M
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31766351
[TBL] [Abstract][Full Text] [Related]
14. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.
Waldmann TA
Mol Cell Endocrinol; 2017 Aug; 451():66-70. PubMed ID: 28214593
[TBL] [Abstract][Full Text] [Related]
15. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells.
Cheng J; Zhang D; Zhou C; Marasco WA
Leuk Res; 2004 Jan; 28(1):71-82. PubMed ID: 14630083
[TBL] [Abstract][Full Text] [Related]
17. Regulation of JAK3 expression and activation in human B cells and B cell malignancies.
Tortolani PJ; Lal BK; Riva A; Johnston JA; Chen YQ; Reaman GH; Beckwith M; Longo D; Ortaldo JR; Bhatia K; McGrath I; Kehrl J; Tuscano J; McVicar DW; O'Shea JJ
J Immunol; 1995 Dec; 155(11):5220-6. PubMed ID: 7594533
[TBL] [Abstract][Full Text] [Related]
18. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
Wang LH; Kirken RA; Erwin RA; Yu CR; Farrar WL
J Immunol; 1999 Apr; 162(7):3897-904. PubMed ID: 10201908
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia.
Alcantara M; Simonin M; Lhermitte L; Touzart A; Dourthe ME; Latiri M; Grardel N; Cayuela JM; Chalandon Y; Graux C; Dombret H; Ifrah N; Petit A; Macintyre E; Baruchel A; Boissel N; Asnafi V
Blood Adv; 2019 Jul; 3(13):1981-1988. PubMed ID: 31270080
[TBL] [Abstract][Full Text] [Related]
20. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
Kleppe M; Soulier J; Asnafi V; Mentens N; Hornakova T; Knoops L; Constantinescu S; Sigaux F; Meijerink JP; Vandenberghe P; Tartaglia M; Foa R; Macintyre E; Haferlach T; Cools J
Blood; 2011 Jun; 117(26):7090-8. PubMed ID: 21551237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]